Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing

Continuous manufacturing may offer a solution to the instability of the U.S. pharmaceutical supply chain. Over 80% of generic drugs and a significant portion of active pharmaceutical ingredients (APIs) are manufactured overseas, making the U.S. vulnerable to geopolitical conflicts, export restrictions, and natural disasters. Traditional production methods often rely on disjointed, batch-based processes that are capital- and time-intensive. These methods can introduce product variability and contamination risks, and they often require large facility footprints. A continuous manufacturing approach can address these challenges by consolidating critical production steps into a single, automated system. These systems are designed to offer better process uniformity, higher resource efficiency, and the ability to more quickly deploy localized production capabilities.